Applications of 2-(Dimethylaminomethyl)-1-Cyclohexanone Hydrochloride in Industrial Manufacturing

2-(Dimethylaminomethyl)-1-Cyclohexanone Hydrochloride plays a significant role as a key intermediate and process chemical in multiple, highly regulated industrial and pharmaceutical production streams. Below are core downstream application scenarios specifying process details, compliance, usage, integration, and end products.

1. Synthesis of Active Pharmaceutical Ingredients (API) for CNS Drug Development

This compound is widely used as an intermediate in the synthesis of certain central nervous system pharmaceutical candidates, where structure–activity precision and batch reliability are critical. Formulation chemists introduce it at the initial stage of heterocycle construction that requires tight control on impurities and enantiomeric excess. The processing workflow involves N-alkylation and cyclization reactions under anhydrous conditions, with full traceability ensured for all input lots.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice (GMP) for Active Pharmaceutical Ingredients
• European Pharmacopeia (Ph. Eur.) Monograph 9.0
• US FDA 21 CFR Part 211
• China Pharmacopeia (ChP) standards

Typical usage ratio

• Employ at 0.85–1.15 molar equivalents per target API intermediate, adjusted for batch yield and byproduct analysis

Downstream process integration

• Added during Stage 1 synthesis, co-charged with base catalysts and solvent under inert gas blanket

Final product types

• CNS agents in solid oral dosage form
• Injectable research compounds
• Clinical trial drug lots

2. Production of Specialty Quaternary Ammonium Salts for Industrial Catalysis

Manufacturers in fine chemical sectors use this material as a quaternization feedstock when producing specialized ammonium salts. The reaction process requires controlled temperature profiles and slow addition to maintain reaction selectivity. End-users benefit from its amine function for generating cationic surfactants and phase transfer catalysts, which support various polymerization and organic transformation operations.

Industry compliance standards

• ISO 9001:2015 Quality Management for Fine Chemicals
• REACH Registration, Evaluation, Authorisation and Restriction of Chemicals (Europe)
• TSCA Inventory Listing (USA)

Typical usage ratio

• Applied at 1.00–1.08 molar equivalents relative to halide reactants, fine-tuned by titration endpoint

Downstream process integration

• Dosed at pre-polymerization quaternization step, followed by aqueous work-up and phase separation

Final product types

• Phase transfer catalysts
• Antistatic agents
• Pre-polymerization surfactants

3. Intermediate for Synthesis of Ketone-Based Fine Chemicals

Chemical manufacturers utilize this raw material as a building block for substituted cyclohexanone derivatives, which see demand in high-value intermediate supply chains. The process involves precision condensation and reductive amination pathways. The chemical’s stability and defined hydrochloride salt structure help limit batch-to-batch variation observed with free bases.

Industry compliance standards

• ISO 14001:2015 Environmental Management in Chemical Manufacturing
• GB/T 19001—Quality Management Systems (China)
• Responsible Care Global Charter Implementation

Typical usage ratio

• Range of 12–18% by mass relative to target ketone product, depending on desired ring substitution

Downstream process integration

• Charged early in multi-step ketone synthesis, reacted under controlled pH, with monitored heating cycles

Final product types

• Substituted cyclohexanones for agrochemical intermediates
• Scents and flavors intermediates
• Custom fine chemical stocks

4. Chemical Intermediate for API Impurity Reference Standard Production

Regulated laboratories and reference standard producers apply this compound in the synthesis of trace-level impurities and related substances, essential for analytical and regulatory purposes. The chemical’s structural specificity supports calibration, analytical method validation, and pharmacopoeial compliance testing in drug manufacturing and release. Controlled conditions and rigorous documentation ensure analytical-grade identity and purity.

Industry compliance standards

• USP <1225> Validation of Compendial Procedures
• ICH Q3A/B Impurity Guidelines
• ISO/IEC 17025 Laboratory Accreditation
• BP (British Pharmacopoeia) Reference Standards

Typical usage ratio

• Used at 0.05–2.5% by weight relative to main API, subject to analytical validation protocols

Downstream process integration

• Charged at initial step of impurity synthesis and later isolated by preparative chromatography

Final product types

• API impurity reference substance vials
• Analytical marker compounds
• Pharmacopoeial impurity standards

5. Building Block for Research and Development in Medicinal Chemistry

This compound finds demand in custom synthesis projects at pharmaceutical research labs and CROs, facilitating rapid analog generation and SAR (structure–activity relationship) exploration. Chemists employ it as a functionalized amine building block under inert conditions to achieve rational scaffold modifications. Detailed batch records and direct supply from GMP-inspected facilities meet the stringent documentation requirements of R&D pipelines.

Industry compliance standards

• OECD Principles of Good Laboratory Practice (GLP)
• US NIH ChemCore procurement compliance
• Internal R&D QA Protocols

Typical usage ratio

• Commonly used at 0.2–0.7 molar equivalents per analog target; adjusted based on synthetic complexity

Downstream process integration

• Dispatched as first-step input or late-stage derivatization agent in discovery route mapping

Final product types

• Small molecule analog libraries
• Lead generation compounds
• Patented molecular scaffolds